Assessment Tool: AIMS
The AIMS is the standard monitoring instrument for tardive dyskinesia (TD) and other antipsychotic- induced movement disorders. Administer at baseline before starting antipsychotic therapy and repeat every 3–6 months. Observe the patient at rest and during activating maneuvers. Any progression requires immediate clinical review — TD may be irreversible once established.
AIMS — Abnormal Involuntary Movement Scale
A 12-item clinician-rated instrument developed by the National Institute of Mental Health (NIMH) to detect and monitor tardive dyskinesia (TD) and other involuntary movement disorders associated with antipsychotic medication use. Rate each body region during observation at rest and during activating maneuvers. Any item rated ≥ 2 in a body region, or two separate body regions rated ≥ 2, warrants clinical follow-up and consideration of medication modification.
Result
AIMS Total (Items 1–7): 0/28
Global assessment (Items 8–10): 0/12
Clinical significance:
AIMS is typically administered at baseline before antipsychotic initiation and repeated every 3–6 months. Scores should be trended over time. Any progression requires immediate provider notification and medication review, as TD may be irreversible once established.